vs
Arm（ARM）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Arm的季度营收约是Revvity的1.6倍（$1.2B vs $772.1M），Arm净利率更高（18.0% vs 12.7%，领先5.2%），Arm同比增速更快（26.3% vs 5.9%），Arm自由现金流更多（$186.0M vs $161.8M），过去两年Arm的营收复合增速更高（24.1% vs 9.0%）
Arm Holdings 是一家总部位于英国剑桥的半导体与软件设计公司。公司设计 Arm CPU 架构，并将处理器设计与相关知识产权授权给全球的芯片厂商和设备制造商。基于 Arm 架构的芯片驱动着绝大多数智能手机，并在笔记本电脑、数据中心服务器和嵌入式设备中占据越来越大的份额。公司于 2023 年 9 月在纳斯达克上市，目前仍由软银控股。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ARM vs RVTY — 直观对比
营收规模更大
ARM
是对方的1.6倍
$772.1M
营收增速更快
ARM
高出20.5%
5.9%
净利率更高
ARM
高出5.2%
12.7%
自由现金流更多
ARM
多$24.2M
$161.8M
两年增速更快
ARM
近两年复合增速
9.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $772.1M |
| 净利润 | $223.0M | $98.4M |
| 毛利率 | 97.6% | — |
| 营业利润率 | 14.9% | 14.5% |
| 净利率 | 18.0% | 12.7% |
| 营收同比 | 26.3% | 5.9% |
| 净利润同比 | -11.5% | 3.9% |
| 每股收益（稀释后） | $0.21 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARMRVTY
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | — | $664.8M | ||
| Q4 24 | $983.0M | $729.4M | ||
| Q3 24 | $844.0M | $684.0M | ||
| Q2 24 | $939.0M | $691.7M | ||
| Q1 24 | — | $649.9M |
净利润ARMRVTY
| Q4 25 | $223.0M | $98.4M | ||
| Q3 25 | $238.0M | $46.7M | ||
| Q2 25 | $130.0M | $53.9M | ||
| Q1 25 | — | $42.2M | ||
| Q4 24 | $252.0M | $94.6M | ||
| Q3 24 | $107.0M | $94.4M | ||
| Q2 24 | $223.0M | $55.4M | ||
| Q1 24 | — | $26.0M |
毛利率ARMRVTY
| Q4 25 | 97.6% | — | ||
| Q3 25 | 97.4% | 53.6% | ||
| Q2 25 | 97.2% | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | 97.2% | — | ||
| Q3 24 | 96.2% | 56.3% | ||
| Q2 24 | 96.5% | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率ARMRVTY
| Q4 25 | 14.9% | 14.5% | ||
| Q3 25 | 14.4% | 11.7% | ||
| Q2 25 | 10.8% | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | 17.8% | 16.3% | ||
| Q3 24 | 7.6% | 14.3% | ||
| Q2 24 | 19.4% | 12.4% | ||
| Q1 24 | — | 6.8% |
净利率ARMRVTY
| Q4 25 | 18.0% | 12.7% | ||
| Q3 25 | 21.0% | 6.7% | ||
| Q2 25 | 12.3% | 7.5% | ||
| Q1 25 | — | 6.4% | ||
| Q4 24 | 25.6% | 13.0% | ||
| Q3 24 | 12.7% | 13.8% | ||
| Q2 24 | 23.7% | 8.0% | ||
| Q1 24 | — | 4.0% |
每股收益（稀释后）ARMRVTY
| Q4 25 | $0.21 | $0.86 | ||
| Q3 25 | $0.22 | $0.40 | ||
| Q2 25 | $0.12 | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | $0.24 | $0.77 | ||
| Q3 24 | $0.10 | $0.77 | ||
| Q2 24 | $0.21 | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.5B | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.8B | $7.3B |
| 总资产 | $10.2B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ARMRVTY
| Q4 25 | $3.5B | $919.9M | ||
| Q3 25 | $3.3B | $931.4M | ||
| Q2 25 | $2.9B | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $2.7B | $1.2B | ||
| Q3 24 | $2.4B | $1.2B | ||
| Q2 24 | $2.5B | $2.0B | ||
| Q1 24 | — | $1.7B |
股东权益ARMRVTY
| Q4 25 | $7.8B | $7.3B | ||
| Q3 25 | $7.4B | $7.4B | ||
| Q2 25 | $7.0B | $7.6B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $6.4B | $7.7B | ||
| Q3 24 | $6.0B | $7.9B | ||
| Q2 24 | $5.7B | $7.9B | ||
| Q1 24 | — | $7.8B |
总资产ARMRVTY
| Q4 25 | $10.2B | $12.2B | ||
| Q3 25 | $9.7B | $12.1B | ||
| Q2 25 | $9.4B | $12.4B | ||
| Q1 25 | — | $12.4B | ||
| Q4 24 | $8.5B | $12.4B | ||
| Q3 24 | $8.1B | $12.8B | ||
| Q2 24 | $7.9B | $13.4B | ||
| Q1 24 | — | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $365.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $186.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 15.0% | 21.0% |
| 资本支出强度资本支出/营收 | 14.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.64× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $1.2B | $509.4M |
8季度趋势，按日历期对齐
经营现金流ARMRVTY
| Q4 25 | $365.0M | $182.0M | ||
| Q3 25 | $567.0M | $138.5M | ||
| Q2 25 | $332.0M | $134.3M | ||
| Q1 25 | — | $128.2M | ||
| Q4 24 | $423.0M | $174.2M | ||
| Q3 24 | $6.0M | $147.9M | ||
| Q2 24 | $-290.0M | $158.6M | ||
| Q1 24 | — | $147.6M |
自由现金流ARMRVTY
| Q4 25 | $186.0M | $161.8M | ||
| Q3 25 | $429.0M | $120.0M | ||
| Q2 25 | $178.0M | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | $360.0M | $149.8M | ||
| Q3 24 | $-47.0M | $125.6M | ||
| Q2 24 | $-319.0M | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率ARMRVTY
| Q4 25 | 15.0% | 21.0% | ||
| Q3 25 | 37.8% | 17.2% | ||
| Q2 25 | 16.9% | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | 36.6% | 20.5% | ||
| Q3 24 | -5.6% | 18.4% | ||
| Q2 24 | -34.0% | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度ARMRVTY
| Q4 25 | 14.4% | 2.6% | ||
| Q3 25 | 12.2% | 2.6% | ||
| Q2 25 | 14.6% | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | 6.4% | 3.4% | ||
| Q3 24 | 6.3% | 3.3% | ||
| Q2 24 | 3.1% | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率ARMRVTY
| Q4 25 | 1.64× | 1.85× | ||
| Q3 25 | 2.38× | 2.97× | ||
| Q2 25 | 2.55× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 1.68× | 1.84× | ||
| Q3 24 | 0.06× | 1.57× | ||
| Q2 24 | -1.30× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARM
| Royalty | $737.0M | 59% |
| Transferred Over Time | $294.0M | 24% |
| Transferred At Point In Time | $211.0M | 17% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
